The mayor stressed: “Providing medical institutions and the population with modern medicines and vaccines is one of our top priorities. Therefore, we provide systematic and anti-crisis support to pharmaceutical companies.”
Among the support measures for pharmaceutical companies in the capital:
– subsidies, loans and loans on favorable terms, as well as tax incentives due to the status of an industrial complex; 7 companies in the pharmaceutical industry have already received this status. For example, the Binnopharm plant in Zelenograd, which became the world’s first site for the production of a COVID-19 vaccine (Sputnik V);
– compensation contracts with investors. One of the first in 2017 was the Biocad company, which under the contract built a complex for the production of, among other things, anti-cancer drugs;
– creation of a large pharmaceutical cluster on the basis of Technopolis Moscow SEZ, which brought together 9 developers and manufacturers of drugs. By 2027, it is planned to increase the number of pharmaceutical production facilities to 15 on this basis.
The pharmaceutical industry is one of the key industries in Moscow, Sobyanin noted and reminded: now 95 pharmaceutical companies employing more than 15 thousand people operate in the city. Moscow produces drugs for the treatment of not only cancer, but also cardiovascular diseases, disorders of the nervous system, diabetes, as well as antibiotics and vaccines.
